JP Morgan Chase’s TriSalus Life Sciences TLSI Stock Holding History

JP Morgan Chase’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$42.3K	Sell	11,402 -748	-6%	-$3.66K	﹤0.01%	6261
2025 Q4	$84.8K	Buy	12,150 +4,629	+62%	+$25.9K	﹤0.01%	5974
2025 Q3	$35K	Sell	7,521 -19	-0.3%	-$89	﹤0.01%	6341
2025 Q2	$41.1K	Buy	7,540 +7,519	+35,805%	+$40.3K	﹤0.01%	5988
2025 Q1	$116	Sell	21 -3	-13%	-$16	﹤0.01%	6858
2024 Q4	$120	Sell	24 -1	-4%	-$4	﹤0.01%	6983
2024 Q3	$115	Buy	25 +5	+25%	+$26	﹤0.01%	6981
2024 Q2	$110	Sell	20 -10,539	-100%	-$89.4K	﹤0.01%	6871
2024 Q1	$103K	Buy	+10,559	New	+$97.5K	﹤0.01%	5660
2022 Q1	–	Sell	-55,000	Closed	-$543K	–	7020
2021 Q4	$543K	Sell	55,000 -195,210	-78%	-$1.94M	﹤0.01%	4778
2021 Q3	$2.48M	Buy	250,210 +250,000	+119,048%	+$2.45M	﹤0.01%	3608
2021 Q2	$2K	Buy	+210	New	+$2.06K	﹤0.01%	6216

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

JP Morgan Chase's TLSI Position: Q1 2026 in Review

JP Morgan Chase reduced its TriSalus Life Sciences (TLSI) stake by 6.2% in Q1 2026, selling an estimated $3.66K and leaving 11,402 shares worth $42.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6261.

JP Morgan Chase first reported a position in TLSI in Q2 2021 and has held it in 12 quarters since. The position peaked at $2.48M in Q3 2021. 84 funds tracked by Wall St. Rank hold TLSI as of Q1 2026.

JP Morgan Chase held 11,402 shares of TriSalus Life Sciences worth $42.3K as of Q1 2026.
JP Morgan Chase sold 748 TriSalus Life Sciences shares in Q1 2026, an estimated $3.66K.
TriSalus Life Sciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6261 holding.
JP Morgan Chase first reported a position in TriSalus Life Sciences in Q2 2021 and has held it in 12 quarters since.
JP Morgan Chase's TriSalus Life Sciences position peaked at $2.48M in Q3 2021.
84 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.